Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Articles|August 18, 2010
Bipolar Disorder Quiz
According to the 2009 Roundtable on Bipolar Disorder in Children and Adolescents, a diagnosis of pediatric bipolar I disorder should be considered dependent on what factors? This and more in this week's quiz.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Treating PTSD Among Veterans at Risk for Suicide
3
Podcast: Not Always Panic. A Cardiologist and Psychiatrist on Reading a Racing Heart
4
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
5